T he mechanism by which NO and NO-generating drugs lead to vasodilatation is not well understood. [1] [2] [3] [4] [5] Recent studies with knockout mice have shown that NO can induce the relaxation of vascular smooth muscle by activation of soluble guanylyl cyclase, production of cGMP, and activation of cGMP-dependent protein kinase I (cGKI). 6, 7 Furthermore, NO and cGMP may regulate vascular tone by signaling pathways that do not require cGKI. 7, 8 The identity of the cellular substrates and mechanisms regulated by cGKI has been discussed controversially. cGKI-mediated smooth muscle relaxation may involve a decrease in the cytosolic Ca 2ϩ concentration ([Ca 2ϩ ] i ) 6, 9, 10 as well as a modulation of the activity of myosin phosphatase, [11] [12] [13] [14] RhoA, 15 or telokin. 16 Overexpression of cGKI in non-smooth muscle cells suggests additional targets. 1, 17 At present, the functional significance of these targets in the regulation of vascular tone is unclear. Moreover, the interpretation of some results obtained with intact vascular smooth muscle cells (VSMCs) may be limited by the fact that the extensively used "specific cGKI inhibitor" KT5823 may not inhibit cGKI activity in intact cells 18 and that cGKI expression decreases during cell culture. 9, 19 The cGKI gene encodes two isoforms, cGKI␣ and cGKI␤, which differ in their amino termini (Ϸ100 amino acids). 20, 21 Both isoforms are expressed in vascular and nonvascular smooth muscle. [22] [23] [24] The amino terminus is involved in homodimerization, regulation of cGMP affinity and kinase activation, and target protein recognition. 1, 2, 25 Recent experiments have shown that the amino terminus of cGKI␣ interacts specifically with the myosin-binding subunit of myosin phosphatase, 12 whereas the amino terminus of cGKI␤ interacts specifically with inositol 1,4,5-trisphosphate receptor-associated cGMP kinase substrate (IRAG), a cGKI substrate protein. 26 In contrast to this detailed information on the biochemistry of the cGKI isoforms, the specific cellular functions of cGKI␣ and cGKI␤ in VSMCs are not known.
We have used cGKI-deficient primary cells to study the functional significance of the endogenous NO/cGMP/cGKI signaling pathway and the specific roles of the cGKI␣ and cGKI␤ isoforms in the regulation of [Ca 2ϩ ] i in VSMCs. This strategy overcomes the limitations of experiments that are based solely on pharmacological tools to dissect cGKIdependent and cGKI-independent NO/cGMP signaling pathways in intact cells. Our results indicate that NO/cGMP inhibits noradrenaline (NA)-induced Ca 2ϩ transients in VSMCs via activation of cGKI␣ but not cGKI␤.
Materials and Methods

Construction and Transfection of Plasmids
A BamHI site was introduced into the region encompassing the stop codon of the bovine cGKI␣ cDNA 20 by polymerase chain reaction-mediated mutagenesis, such that the wild-type sequence GAC TTC TAA TGT encoding Asp Phe Stop was changed into GAC TTG GAT CCA encoding Asp Leu Asp Pro. The 2.1-kb EcoRI-BamHI fragment of the mutated cGKI␣ cDNA was inserted into the EcoRI-BamHI sites of pEGFP-N1 (Clontech), where EGFP indicates enhanced green fluorescent protein, resulting in the vector pCMVcGKI␣EGFP, where CMV indicates cytomegalovirus. The vector pCMV-cGKI␤EGFP was constructed by replacing the 1.8-kb EcoRIPacI fragment of pCMV-cGKI␣EGFP with the 1.8-kb EcoRI-PacI fragment of the bovine cGKI␤ cDNA 27 encompassing the 5Ј region, which differs between the ␣ and ␤ isoform. The CMV promoterdriven expression vectors pCMV-cGKI␣EGFP and pCMVcGKI␤EGFP encode in-frame fusions of EGFP to the carboxy termini of cGKI␣ and cGKI␤, respectively. The identities of all constructs were verified by DNA sequence analysis. VSMCs were transiently transfected with the use of LipofectAMINE (Life Technologies) and then maintained in serum-free medium for 2 days before analysis. COS-7 cells were transiently transfected by using the calcium phosphate method and were analyzed 2 days after transfection.
Cell Culture and Measurement of [Ca 2؉ ] i
VSMCs were isolated from aortas of 3-to 6-week-old litter-matched wild-type (cGKI ϩ/ϩ ) and cGKI-knockout (cGKI Ϫ/Ϫ ) mice 28 by enzymatic digestion and grown in DMEM (Life Technologies) supplemented with 10% FCS. 29 The identity of the cells was confirmed by staining with a smooth muscle ␣-actin antibody (Sigma Chemical Co). Subconfluent cells in their first passage were maintained in serum-free medium for 2 days and then in buffer A (mmol/L: NaCl 140, KCl 5.0, MgSO 4 
Fluorescence Imaging
Imaging of EGFP fluorescence was performed by use of a custombuilt two-photon laser-scanning microscope based on a mode-locked titanium-sapphire laser system operated at 790-nm center wave length, 80-MHz pulse repeat, and Ͻ100-femtosecond pulse width (Tsunami and Millenia, Spectra Physics) and a laser-scanning system (MRC 1024, Bio-Rad) mounted on an upright microscope (BX50WI, Olympus) equipped with a ϫ40 water immersion objective (Olympus). Cells were perfused with buffer A or buffer A containing 1 mmol/L 8-Br-cGMP. Every 5 to 10 minutes, 14 to 20 focal planes 0.3 to 0.5 m apart were scanned. These were later projected into a single image. Images were analyzed offline with NIH Image software.
Miscellaneous Methods
Cyclic nucleotides and cGKI activity were determined by using enzyme immunoassay kits (Cayman Chemical) and an in vitro kinase assay, 31 respectively. Western blot analysis and immunocytochemistry were performed by using polyclonal rabbit antisera detecting cGKI, 6 
Results
VSMCs were isolated from aortas of cGKI ϩ/ϩ mice and cGKI Ϫ/Ϫ mice, which are deficient for both the cGKI␣ and 
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cGKI␤ isoform. 28 Cells were studied in their first passage to limit phenotypic modulation, downregulation of cGKI expression, 9, 19 and potential deregulation of other components of the NO/cGMP pathway, which may occur after repeated passaging of VSMCs. The morphology and general growth characteristics of cGKI Ϫ/Ϫ cells were indistinguishable from those of cGKI ϩ/ϩ cells ( Figure 1A and data not shown). Basal levels of cGMP as well as cAMP were similar in cGKI ϩ/ϩ and cGKI Ϫ/Ϫ cells ( Figure 1B) . Treatment with the NO donor DEA-NO (10 mol/L) increased cGMP levels Ϸ50-fold in cGKI ϩ/ϩ and cGKI Ϫ/Ϫ cells, whereas cAMP levels were not increased by treatment with DEA-NO (10 mol/L) or the membrane-permeable cGMP analogue 8-Br-cGMP (1 mmol/L) ( Figure 1B ). Western blot analysis showed that cGKI was endogenously expressed in cGKI ϩ/ϩ but not in cGKI Ϫ/Ϫ cells ( Figure 1C , top panels). DEA-NO (10 mol/L) as well as 8-Br-cGMP (1 mmol/L) stimulated the phosphorylation of VASP, a substrate for both cGKI-and cAMPdependent protein kinases, 32 in cGKI ϩ/ϩ but not in cGKI Ϫ/Ϫ cells ( Figure 1C , bottom panels). These results indicated that the cGKI ϩ/ϩ VSMCs analyzed in the present study endogenously expressed a functional NO/cGMP/cGKI pathway and that DEA-NO as well as 8-Br-cGMP activated the endogenous cGKI in intact cells without increasing cAMP levels or cAMP-dependent protein kinase activity. Furthermore, the lack of functional cGKI in the cGKI Ϫ/Ϫ cells did not affect the general growth properties and cyclic nucleotide levels compared with those in the cGKI ϩ/ϩ cells. Immunocytochemistry with a cGKI-specific antibody indicated that the endogenous cGKI was concentrated in the perinuclear/endoplasmic reticulum region ( Figure 1D ). Western blot analysis ( Figure 1E ) showed that the VSMCs expressed both the cGKI␣ and cGKI␤ isoform as well as the recently identified cGKI substrate, IRAG. 10 To evaluate the functional significance of the endogenous NO/cGMP/cGKI pathway for the regulation of To confirm the role of cGKI in NO/cGMP-dependent Ca 2ϩ regulation and to analyze the specific functions of the cGKI␣ and cGKI␤ isoforms, cells were transfected with expression plasmids encoding the cGKI isoforms. EGFP was fused to the carboxy terminus of each cGKI isoform to identify transfected cells as well as the intracellular localization of each isoform. Both the cGKI␣-EGFP and cGKI␤-EGFP fusion constructs were expressed with the expected apparent molecular weights ( Figure 3A ) and had cGMP-dependent kinase activities and activation constants similar to the respective wild-type isoforms ( Figure 3B ). Browning et al 33 recently reported a fusion construct similar to cGKI␣-EGFP that had constitutive (cGMPindependent) kinase activity. In contrast, the kinase activity of the cGKI␣-EGFP as well as the cGKI␤-EGFP fusion protein generated in the present study was stimulated Ϸ10-fold by cGMP ( Figure 3B) , allowing for the functional analysis of the cGKI isoforms before and after activation by cGMP in living cells.
In the next set of experiments, we investigated whether [Ca 2ϩ ] i was regulated by cGKI␣ and/or cGKI␤ in VSMCs. Figure 2D ) could be rescued by transfection of cGKI␣-EGFP but not cGKI␤-EGFP (Figure 4) . These results indicate that specifically the cGKI␣ isoform but not the cGKI␤ isoform inhibits NA-induced Ca 2ϩ transients in VSMCs.
The intracellular localization of the cGKI-EGFP fusion proteins was studied in live VSMCs by fluorescence imaging of the EGFP fluorescence with the use of twophoton microscopy. As illustrated in Figure 5 , the relative fluorescence intensity within the perinuclear region was significantly higher in cells transfected with cGKI␣-EGFP than in cells transfected with cGKI␤-EGFP. Addition of 8-Br-cGMP (1 mmol/L for up to 60 minutes) did not alter the distribution of cellular EGFP fluorescence ( Figure 5C and data not shown). These results suggest that the cGKI␣ isoform is preferentially localized to the perinuclear/ endoplasmic reticulum region, whereas the cGKI␤ isoform is more homogeneously distributed in the cytosol. Neither cGKI isoform had translocated into the nucleus nor had either shown any other redistribution in the presence of 8-Br-cGMP. Similar results were obtained with a constitutively active cGKI␣-EGFP fusion protein, which was detected in the perinuclear region but not in the nucleus of various non-smooth muscle cell lines. 33 
Discussion
The present study analyzed, for the first time, the specific functions of cGKI␣ and cGKI␤ for vascular NO/cGMP/cGKI signaling. Both cGKI isoforms are endogenously expressed in VSMCs. We developed a genetic deletion/rescue strategy that appeared to be superior to the use of inhibitors, because isoform-specific cGKI inhibitors are not available and the in vivo efficiency of the cGKI-specific inhibitor KT5823 is variable. 18 DEA-NO stimulated endogenous cGMP synthesis in both cGKI ϩ/ϩ and cGKI Ϫ/Ϫ VSMCs, whereas DEA-NO as The specific functions of the cGKI isoforms were dissected by using EGFP fusion proteins. The kinase activity of these fusion proteins was stimulated Ϸ10-fold by cGMP with activation constants similar to the respective wild-type isoforms, suggesting that the expressed fusion proteins retained the properties of the native enzymes. Interestingly, the defective Ca 2ϩ regulation in cGKI Ϫ/Ϫ VSMCs was restored by transfection of cGKI␣-EGFP but not cGKI␤-EGFP, indicating that the inhibition of NA-induced Ca 2ϩ transients by NO/cGMP is mediated via the activation of cGKI␣ but not cGKI␤. In agreement with this result, earlier work has shown that hormoneinduced Ca 2ϩ transients are inhibited by cGKI␣ in stably transfected CHO cells 30, 34 but not by cGKI␤ in stably transfected 293 cells and 3T6 cells. 35 However, cGKI␤ inhibited bradykinin-induced Ca 2ϩ transients in the presence of its substrate IRAG in transiently transfected COS cells. 10, 26 transients. cGKI has been implicated in the regulation of smooth muscle growth and phenotypic modulation. 5 IRAG has been postulated to be a tumor suppressor in myeloid cells. 42 These findings support the hypothesis that cGKI␤ and IRAG may regulate cell growth and differentiation, which may be affected by the release of Ca 2ϩ from specific stores not involved in the regulation of vascular tone.
Another function of cGKI␤ could be the translocation of the activated enzyme into the nucleus and activation of the fos promoter. [43] [44] [45] By fluorescence imaging of cGKI␣-EGFP and cGKI␤-EGFP fusion proteins in living cells ( Figure 5 ) as well as by immunocytochemical analysis of endogenous cGKI in fixed cells (R.F., F.H., unpublished data, 2002), we did not detect nuclear translocation or any other redistribution of cGKI isoforms in VSMCs on treatment with 1 mmol/L 8-Br-cGMP for up to 60 minutes, although this drug concentration clearly activated cGKI in intact cells ( Figure 1C) . Similar results were obtained by other groups in other cells with the use of immunocytochemistry 46 or EGFP fusion constructs. 33 According to these findings, it seems unlikely that either cGKI isoform translocates into the nucleus of VSMCs.
Taken together, the present study identifies a specific role for cGKI␣ in NO/cGMP-dependent regulation of [Ca 2ϩ ] i in VSMCs. Reduction of the [Ca 2ϩ ] i level by cGKI␣ may be one component of signaling pathways regulating vascular tone in vivo. Additional cGKI␣-dependent mech- anisms may involve changes in the Ca 2ϩ sensitivity of the contractile machinery, 4 the translocation of Rho A, 15 the activity of myosin phosphatase, 12 and the membrane potential. 3, 41 
